BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

350 related articles for article (PubMed ID: 36949946)

  • 21. Involving stemness factors to improve CAR T-cell-based cancer immunotherapy.
    Noraldeen SAM; Rasulova I; Lalitha R; Hussin F; Alsaab HO; Alawadi AH; Alsaalamy A; Sayyid NH; Alkhafaji AT; Mustafa YF; Shayan SK
    Med Oncol; 2023 Oct; 40(11):313. PubMed ID: 37779152
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Engineering Next-Generation CAR-T Cells: Overcoming Tumor Hypoxia and Metabolism.
    Gao TA; Chen YY
    Annu Rev Chem Biomol Eng; 2022 Jun; 13():193-216. PubMed ID: 35700528
    [TBL] [Abstract][Full Text] [Related]  

  • 23. CAR-T Cells and Oncolytic Viruses: Joining Forces to Overcome the Solid Tumor Challenge.
    Guedan S; Alemany R
    Front Immunol; 2018; 9():2460. PubMed ID: 30405639
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Nanotechnology-based chimeric antigen receptor T-cell therapy in treating solid tumor.
    Zuo YH; Zhao XP; Fan XX
    Pharmacol Res; 2022 Oct; 184():106454. PubMed ID: 36115525
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Immunosuppression in tumor immune microenvironment and its optimization from CAR-T cell therapy.
    Liu Z; Zhou Z; Dang Q; Xu H; Lv J; Li H; Han X
    Theranostics; 2022; 12(14):6273-6290. PubMed ID: 36168626
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Chimeric Antigen Receptor (CAR)-T Cell Immunotherapy Against Thoracic Malignancies: Challenges and Opportunities.
    Chen L; Chen F; Niu H; Li J; Pu Y; Yang C; Wang Y; Huang R; Li K; Lei Y; Huang Y
    Front Immunol; 2022; 13():871661. PubMed ID: 35911706
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Preclinical Models in Chimeric Antigen Receptor-Engineered T-Cell Therapy.
    Siegler EL; Wang P
    Hum Gene Ther; 2018 May; 29(5):534-546. PubMed ID: 29390873
    [TBL] [Abstract][Full Text] [Related]  

  • 28. CAR-T Plus Radiotherapy: A Promising Combination for Immunosuppressive Tumors.
    Qin VM; Haynes NM; D'Souza C; Neeson PJ; Zhu JJ
    Front Immunol; 2021; 12():813832. PubMed ID: 35095911
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Relapse after CAR-T cell therapy in B-cell malignancies: challenges and future approaches.
    Gu T; Zhu M; Huang H; Hu Y
    J Zhejiang Univ Sci B; 2022 Oct; 23(10):793-811. PubMed ID: 36226535
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The landscape of chimeric antigen receptor T cell therapy in breast cancer: Perspectives and outlook.
    Zhang H; Zhu S; Deng W; Li R; Zhou H; Xiong H
    Front Immunol; 2022; 13():887471. PubMed ID: 35935930
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Hurdles to breakthrough in CAR T cell therapy of solid tumors.
    Marofi F; Achmad H; Bokov D; Abdelbasset WK; Alsadoon Z; Chupradit S; Suksatan W; Shariatzadeh S; Hasanpoor Z; Yazdanifar M; Shomali N; Khiavi FM
    Stem Cell Res Ther; 2022 Apr; 13(1):140. PubMed ID: 35365241
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Perspectives on Chimeric Antigen Receptor T-Cell Immunotherapy for Solid Tumors.
    Kosti P; Maher J; Arnold JN
    Front Immunol; 2018; 9():1104. PubMed ID: 29872437
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Tumor Microenvironment Immunosuppression: A Roadblock to CAR T-Cell Advancement in Solid Tumors.
    Johnson A; Townsend M; O'Neill K
    Cells; 2022 Nov; 11(22):. PubMed ID: 36429054
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Combining Oncolytic Viruses with Chimeric Antigen Receptor T Cell Therapy.
    McGrath K; Dotti G
    Hum Gene Ther; 2021 Feb; 32(3-4):150-157. PubMed ID: 33349123
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Remodeling of Tumor Microenvironment by Tumor-Targeting Nanozymes Enhances Immune Activation of CAR T Cells for Combination Therapy.
    Zhu L; Liu J; Zhou G; Liu TM; Dai Y; Nie G; Zhao Q
    Small; 2021 Oct; 17(43):e2102624. PubMed ID: 34378338
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Efficient combination of radiotherapy and CAR-T - A systematic review.
    Szlasa W; Sztuder A; Kaczmar-Dybko A; Maciejczyk A; Dybko J
    Biomed Pharmacother; 2024 May; 174():116532. PubMed ID: 38574625
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Challenges in the Treatment of Glioblastoma by Chimeric Antigen Receptor T-Cell Immunotherapy and Possible Solutions.
    Zhang P; Zhang Y; Ji N
    Front Immunol; 2022; 13():927132. PubMed ID: 35874698
    [TBL] [Abstract][Full Text] [Related]  

  • 38. CAR race to cancer immunotherapy: from CAR T, CAR NK to CAR macrophage therapy.
    Pan K; Farrukh H; Chittepu VCSR; Xu H; Pan CX; Zhu Z
    J Exp Clin Cancer Res; 2022 Mar; 41(1):119. PubMed ID: 35361234
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Prospects and challenges for use of CAR T cell therapies in solid tumors.
    Ramakrishna S; Barsan V; Mackall C
    Expert Opin Biol Ther; 2020 May; 20(5):503-516. PubMed ID: 32125191
    [No Abstract]   [Full Text] [Related]  

  • 40. Prospects for chimeric antigen receptor-modified T cell therapy for solid tumors.
    Zhang E; Gu J; Xu H
    Mol Cancer; 2018 Jan; 17(1):7. PubMed ID: 29329591
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 18.